

Supplementary materials

Table S1: Search strategy conducted in Ovid

Search strategy
#1 <i>NTRK</i> .mp.
#2 TRK fusion\$.mp.
#3 kinase fusion\$.mp.
#4 \$ <i>NTRK</i> \$.mp.
#5 \$ <i>TRK</i> \$.ti,ab.
#6 or/1-5
#7 (cancer\$ or \$carcinoma\$ or \$sarcoma\$ or melanoma\$ or tumor\$ or tumour\$ or \$blastoma\$ or \$cytoma\$ or \$glioma\$ or neoplasm\$ or nephroma\$).ti,ab.
#8 6 and 7
#9 limit 8 to human
#10 limit 9 to (randomized controlled trial or controlled clinical trial or phase 1 clinical trial or phase 2 clinical trial or phase 3 clinical trial or phase 4 clinical trial)
#11 9 not 10
#12 (letter or editorial or comment or news or newspaper article).pt.
#13 animals/ not (humans/ and animals/)
#14 case reports/
#15 in vitro.pt.
#16 or/12-15
#17 11 not 16
#18* - limit 17 to yr="2018-Current" limit 17 to yr="2019 -Current"

* There was no year limit for the original search on December 6, 2018. The first updated search was limited from 2018 to 2019. The final SLR search was limited from 2019 to 2020.

Table S2: Search strategy conducted in PubMed

Search strategy
(TRK or NTRK or NTRK1 or NTRK2 or NTRK3 or tropomyosin) and (fusion or rearrangement) NOT (review[ptyp])
((genomic OR gene) AND (profiling OR fusion OR rearrangement)) AND ("lung cancer" OR "lung adenocarcinoma") NOT (review[ptyp])
((genomic OR gene) AND (profiling OR fusion OR rearrangement)) AND ("colorectal cancer" OR "colorectal carcinoma") NOT (review[ptyp])
((genomic OR gene) AND (profiling OR fusion OR rearrangement)) AND "thyroid cancer" NOT (review[ptyp])
((genomic OR gene) AND (profiling OR fusion OR rearrangement)) AND sarcoma NOT (review[ptyp])
((genomic OR gene) AND (profiling OR fusion OR rearrangement)) AND pediatric AND cancer NOT (review[ptyp])

genomic OR gene) AND (profiling OR fusion OR rearrangement))
AND (CNS OR brain) AND cancer NOT (review[ptyp])

ptyp=publication type

Duplicates were removed. The searches were run through Dec 2019.

Table S3. NTRK fusion frequencies by histology for the meta-analysis

Tumor group	Tumor histology	Histology number	Number of studies included in the meta-analysis	Frequency	Confidence interval	Standard error	Methods
Head and Neck	Squamous Cell Carcinoma of Head and Neck ^{30,31}	1	2	0.38	0.01 - 0.76	0.19	Fixed effect model (meta-analysis)
	Head and Neck Carcinoma ^{32,33}	2	1	0.00			Single study zero frequency
Salivary Gland	Mammary Analogue Secretory Carcinoma (also called secretory salivary gland cancer) ³⁴⁻⁴¹	3	8	79.68	62.84 - 96.51	8.59	Fixed effect model (meta-analysis)
	Salivary Gland Carcinoma ⁹	4	1	5.08	2.73 - 8.53	1.41	Single study (Binomial, Exact approach)
	Acinic Cell Carcinoma of Salivary Gland ⁴²	5	1	11.11	4.19 - 22.63	4.54	Single study (Binomial, Exact approach)
	Adenoid Cystic Carcinoma of Salivary Gland ³⁷	6	1	0.00			Single study zero frequency
	Low Grade Mucoepidermoid carcinoma ³⁹	7	1	20.00	5.73 - 43.66	10.00	Single study (Binomial, Exact approach)
	Pleomorphic Adenoma ^{37,39}	8	2	50.47	0.00 - 100.00	46.90	Random effect model (meta-analysis)
Eye	Retinoblastoma ³⁰	9	1	0.00			Single study zero frequency
	Uveal melanoma ^{30,31,43}	10	3	0.00	0.00 - 1.04	0.53	Fixed effect model (meta-analysis)
Lacrimal Gland Carcinoma	Lacrimal gland carcinoma ⁴⁴	11	1	0.29	0.01 - 1.58	0.29	Single study (Binomial, Exact approach)
Brain, CNS	Glioma ^{32,33,45}	12	2	0.99	0.00 - 2.79	0.92	Random effect model (meta-analysis)
	Low Grade Glioma ^{30,31,46}	13	3	0.88	0.22 - 1.54	0.34	Random effect model (meta-analysis)
	High Grade Glioma ⁴⁶	14	1	21.21	0.98 - 38.91	8.02	Single study (Binomial, Exact approach)
	Glioblastoma, Glioblastoma	15	7	0.78	0.39 - 1.18	0.20	Random effect model (meta-analysis)

Tumor group	Tumor histology	Histology number	Number of studies included in the meta-analysis	Frequency	Confidence interval	Standard error	Methods
	Multiforme (all variants) ^{4,30,31,47-50}						
	Anaplastic Astrocytoma (all variants) ⁵¹	16	1	0.00			Single study zero frequency
	Diffuse Astrocytoma (all variants) ⁵¹	17	1	0.00			Single study zero frequency
	Pilocytic Astrocytoma (all variants) ⁵²	18	1	0.00			Single study zero frequency
	Anaplastic Oligodendrogioma (all variants) ⁵¹	19	1	0.00			Single study zero frequency
	Diffuse Leptomeningeal Glioneuronal Tumor ⁵³	20	1	10.00	2.11 - 26.53	5.77	Single study (Binomial, Exact approach)
	Glial, Glioneuronal, and Ependymal ⁵⁴	21	1	3.28	0.40 - 11.35	2.32	Single study (Binomial, Exact approach)
	Glioma/Neuroepithelial Tumor ⁹	22	1	0.55	0.24 - 1.07	0.19	Single study (Binomial, Exact approach)
	Oligodendrogioma (all variants) ⁵¹	23	1	0.00			Single study zero frequency
	High Grade Glioma, Pediatric ^{30,55}	24	2	6.19	3.11 - 9.28	1.57	Fixed effect model (meta-analysis)
	Low Grade Glioma, Pediatric ^{30,56}	25	2	1.61	0.00 - 3.33	0.87	Fixed effect model (meta-analysis)
	Pilocytic Astrocytoma, Pediatric ^{57,58}	26	2	3.18	0.07 - 6.29	1.59	Fixed effect model (meta-analysis)
	Ependymoma, Pediatric ³⁰	27	1	0.00			Single study zero frequency
	Choroid Plexus Carcinoma, Pediatric ³⁰	28	1	0.00			Single study zero frequency
	Neuroblastoma, Pediatric ^{30,58}	29	2	0.00	0.00 - 0.36	0.18	Fixed effect model (meta-analysis)
	Meduloblastoma, Pediatric ³⁰	30	1	0.00			Single study zero frequency
	Diffuse Intrinsic Pontine Glioma, Pediatric ⁵⁹	31	1	4.76	0.12 - 23.82	4.76	Single study (Binomial, Exact approach)
	Dysembryoplastic neuroepithelial tumors, Pediatric ⁶⁰	32	1	3.03	0.08 - 15.76	3.03	Single study (Binomial, Exact approach)
Thyroid Cancer	Thyroid Carcinoma ^{4,9,30,31,61}	33	5	2.60	1.83 - 3.37	0.39	Fixed effect model (meta-analysis)

Tumor group	Tumor histology	Histology number	Number of studies included in the meta-analysis	Frequency	Confidence interval	Standard error	Methods
	Papillary Thyroid Carcinoma ⁶²⁻⁷⁴	34	13	1.89	1.04 - 2.73	0.43	Random effect model (meta-analysis)
	Follicular Thyroid Carcinoma (all variants) ⁷¹	35	1	0.00			Single study zero frequency
	Anaplastic Thyroid Carcinoma ^{69,70,75,76}	36	4	0.94	0.00 - 1.98	0.53	Fixed effect model (meta-analysis)
	Medullary Thyroid Carcinoma ⁶⁹	37	1	0.00			Single study zero frequency
	Hürthle Cell Carcinoma ⁷¹	38	1	2.86	0.07 - 14.92	2.86	Single study (Binomial, Exact approach)
	Poorly Differentiated Thyroid Carcinoma ⁷⁵	39	1	2.44	0.06 - 12.86	2.44	Single study (Binomial, Exact approach)
	Focal Anaplastic Thyroid Carcinoma/Poorly Differentiated Thyroid Carcinoma ⁷⁰	40	1	0.00			Single study zero frequency
	Papillary Thyroid Carcinoma, Pediatric ⁷⁷	41	1	25.93	11.1 - 46.28	9.80	Single study (Binomial, Exact approach)
	Differentiated Thyroid Cancer, Pediatric ⁷⁸	42	1	22.22	6.41 - 47.64	11.11	Single study (Binomial, Exact approach)
Thymus	Thymoma ^{30,31}	43	2	0.00	0.00 - 0.82	0.42	Fixed effect model (meta-analysis)
Lung Cancer	Lung cancer NOS ⁷⁹	44	1	0.02	0.00- 0.12	0.02	Single study (Binomial, Exact approach)
	Lung Adenocarcinoma ^{9,10,30,31,61,79-88}	45	15	0.10	0.04 - 0.16	0.03	Random effect model (meta-analysis)
	Non-Small Cell Lung Cancer ^{4,89,90}	46	4	0.17	0.09 - 0.25	0.04	Random effect model (meta-analysis)
	Lung Adenosquamous Carcinoma ⁸⁷	47	1	0.00			Single study zero frequency
	Small Cell Lung Cancer ^{10,79,91}	48	3	0.32	0.00 - 1.09	0.39	Random effect model (meta-analysis)
	Squamous Cell Carcinoma of the Lung ^{30,31,79,80,85-87}	49	7	0.00	0.00 - 0.09	0.05	Fixed effect model (meta-analysis)
	Large Cell Carcinoma of the Lung ⁹²	50	1	0.00			Single study zero frequency
	Mesothelioma ^{30,31}	51	2	0.00	0.00 - 1.13	0.57	Fixed effect model (meta-analysis)

Tumor group	Tumor histology	Histology number	Number of studies included in the meta-analysis	Frequency	Confidence interval	Standard error	Methods
Esophageal Cancer	Gastric, Esophageal, Squamous Cell Cancer ^{10,30,31}	52	3	0.07	0.00 - 0.58	0.26	Fixed effect model (meta-analysis)
	Gastric and Esophageal Adenocarcinoma ⁹³	53	1	0.00			Single study zero frequency
Gastric Cancer	Gastric, Stomach, Adenocarcinoma ^{30,31,94}	54	3	0.00	0.00 - 0.24	0.12	Fixed effect model (meta-analysis)
Pancreatic Cancer	Pancreatic Adenocarcinoma ^{9,30,31,95}	55	4	0.31	0.09 - 0.53	0.11	Fixed effect model (meta-analysis)
Liver and Biliary Tract Cancer	Liver, Hepatocellular Carcinoma ^{10,30,31}	56	3	0.05	0.00 - 0.29	0.12	Fixed effect model (meta-analysis)
	Biliary Tract Cancer ^{9,10,30,31,49,96,97}	57	7	0.20	0.00 - 0.43	0.12	Fixed effect model (meta-analysis)
Colorectal and Colon Cancer	Colorectal Adenocarcinoma ^{4,9,10,30,94,98-108}	58	16	0.26	0.15 - 0.36	0.05	Random effect model (meta-analysis)
	Colon Adenocarcinoma/Cancer ^{31,49}	59	2	0.46	0.00 - 0.97	0.26	Random effect model (meta-analysis)
	Rectal Carcinoma ³⁰	60	1	0.00			Single study zero frequency
Bladder Cancer	Bladder Carcinoma ⁶¹	61	1	0.00			Single study zero frequency
	Bladder Urothelial Carcinoma ^{30,31}	62	2	0.15	0.00 - 0.60	0.23	Random effect model (meta-analysis)
Rectum Cancer	Rectum Adenocarcinoma ³¹	63	1	0.00			Single study zero frequency
Adrenal Gland	Adrenocortical Carcinoma, Adult ^{30,31}	64	2	0.00	0.00 - 1.24	0.63	Fixed effect model (meta-analysis)
	Adrenocortical Carcinoma, Pediatric ³⁰	65	1	0.00			Single study zero frequency
	Pheochromocytoma and Paraganglioma of the Adrenal Gland ³¹	66	1	0.00			Single study zero frequency
Kidney Cancer	Congenital Mesoblastic Nephroma (all subsets) ¹⁰⁹	67	1	21.52	13.06 - 32.20	5.22	Single study (Binomial, Exact approach)
	Renal Clear Cell Carcinoma ^{30,31}	68	2	0.00	0.00 - 0.18	0.09	Fixed effect model (meta-analysis)
	Renal Papillary Cell Carcinoma ^{30,31}	69	2	0.00	0.00 - 0.34	0.17	Fixed effect model (meta-analysis)
	Renal Chromophobe Tumor ^{30,31}	70	2	0.00	0.00 - 1.48	0.76	Fixed effect model (meta-analysis)
	Kidney, Wilms Tumor ³⁰	71	1	0.00			Single study zero frequency

Tumor group	Tumor histology	Histology number	Number of studies included in the meta-analysis	Frequency	Confidence interval	Standard error	Methods
	Kidney Cancer ⁶¹	72	1	0.00			Single study zero frequency
Appendiceal cancer	Appendiceal Adenocarcinoma ^{9,32,33,49}	73	3	0.56	0.00 - 1.27	0.36	Fixed effect model (meta-analysis)
Breast Cancer	Invasive Breast Carcinoma ^{4,30,31,49,110}	74	5	0.10	0.03 - 0.18	0.04	Fixed effect model (meta-analysis)
	Invasive Breast Lobular Carcinomas ¹¹⁰	75	1	0.00			Single study zero frequency
	Breast Carcinoma ^{9,61}	76	2	0.14	0.04 - 0.24	0.05	Fixed effect model (meta-analysis)
	Secretory Breast Carcinoma ^{35,110-113}	77	5	92.87	72.62 - 100.00	10.33	Fixed effect model (meta-analysis)
Cervical Cancer	Cervical Carcinoma ^{4,30,31}	78	3	0.36	0.00 - 0.81	0.23	Fixed effect model (meta-analysis)
Uterine Cancer	Gyno, Uterine / Endometrical Carcinoma ^{30,31}	79	2	0.00	0.00 - 0.56	0.28	Fixed effect model (meta-analysis)
Ovarian Cancer	Gyno, Ovarian Carcinoma ³⁰	80	1	0.00			Single study zero frequency
	Ovarian Serous Cystadenocarcinoma ³¹	81	1	0.00			Single study zero frequency
Prostate Cancer	Prostate Cancer ^{61,114}	82	2	0.00	0.00 - 0.73	0.37	Fixed effect model (meta-analysis)
	Prostate Adenocarcinoma ^{30,31}	83	2	0.00	0.00 - 0.20	0.10	Fixed effect model (meta-analysis)
Testicular Tumour	Testicular Germ Cell Tumors ^{30,31}	84	2	0.00	0.00 - 0.64	0.33	Fixed effect model (meta-analysis)
Melanoma	Melanoma (cutaneous) ^{9,30,31,94}	85	4	0.31	0.07 - 0.55	0.12	Fixed effect model (meta-analysis)
	Acral Melanoma ¹¹⁵	86	1	2.46	0.51 - 7.02	1.42	Single study (Binomial, Exact approach)
	Pigmented Spindle Cell Nevus of Reed ¹¹⁶	87	1	56.52	34.49 - 76.81	15.68	Single study (Binomial, Exact approach)
	Melanoma, Spitz Tumors and Spitzoid Melanoma ¹¹⁶⁻¹²⁰	88	5	5.56	0.86 - 10.25	2.40	Random effect model (meta-analysis)
Bone Sarcoma	Bone Sarcoma, Osteosarcoma ³⁰	89	1	0.00			Single study zero frequency
	Bone Sarcoma, Ewing Sarcoma ^{30,121}	90	2	0.00	0.00 - 1.10	0.56	Fixed effect model (meta-analysis)
Soft Tissue Sarcoma	Fibrosarcoma, infantile (congenital) ^{122,123}	91	2	90.56	67.42 - 100.00	11.80	Fixed effect model (meta-analysis)

Tumor group	Tumor histology	Histology number	Number of studies included in the meta-analysis	Frequency	Confidence interval	Standard error	Methods
	Inflammatory Myofibroblastic Tumors ¹²⁴⁻¹²⁶	92	3	1.15	0.00 - 3.70	1.30	Random effect model (meta-analysis)
	Soft Tissue Sarcoma, Uterine Sarcoma ^{4,31,49}	93	3	0.34	0.00 - 0.78	0.23	Fixed effect model (meta-analysis)
	Gastrointestinal Stromal Tumour ^{127,128}	94	2	0.61	0.00 - 1.65	0.53	Fixed effect model (meta-analysis)
	Sarcoma, Rhabdomyosarcoma ³⁰	95	1	0.00			Single study zero frequency
Sarcoma, Sarcoma (NOS)	Sarcoma NOS ^{9,30,31,49,129}	96	5	0.75	0.45 - 1.04	0.15	Fixed effect model (meta-analysis)
Neuroendocrine Tumour	Pheochromocytoma and Paraganglioma of the Neuroendocrine ³⁰	97	1	0.00			Single study zero frequency
	Neuroendocrine Tumors ^{9,130,131}	98	3	0.26	0.07 - 0.44	0.10	Fixed effect model (meta-analysis)

Table S4: Worldwide overall *NTRK* gene fusion tumour crude incidence in 2018

Tumour type	Tumour crude incidence (per 100,000)	Tumour incidence reference	Relevant histology	Histology proportion within tumour	Histology proportion reference	NTRK histology frequency from SLR MA		NTRK Incidence per tumour (per 100,000)
						%	95% CI	
Head and Neck Cancer*	11.59	Ferlay J et al. 2018.	squamous cell carcinoma	90%	Gregoire V et al. 2010. Lambert R et al. 2011.	0.38%	0.01 - 0.76%	0.0396
Eye	-	-	retinoblastoma	-	-	0%	-	0.0000
Lacrimal Gland Cancer	0.13	von Holstein SL et al. 2013. (EU)	lacrimal gland carcinoma	100%	NA.	0.29%	0.01 - 1.58%	0.0004
Brain, CNS	3.90	Ferlay J et al. 2018.	glioma	81%	Ostrum QT et al. 2018.	0.99%	0.00 - 2.79%	0.0313
Thyroid Cancer	7.40	Ferlay J et al. 2018.	thyroid carcinoma	100%	-	2.60%	1.83 - 3.37%	0.1924
Thymus	-	-	thymoma	-	-	0%	0.00 - 0.82%	0.0000
Lung Cancer	27.40	Ferlay J et al. 2018.	small cell	13%	Planchard D et al. 2018. Fruh M et al. 2013.	0.32%	0.00 - 1.09%	0.0114
			non-small cell	87%	Planchard D et al. 2018. Fruh M et al. 2013.	0.17%	0.09 - 0.25%	0.0405
Mesothelioma	-	-	mesothelioma	-	-	0%	0.00 - 1.13%	0.0000
Esophageal Cancer	7.50	Ferlay J et al. 2018.	squamous cell carcinoma	90%	Lordick F et al. 2016.	0.07%	0.00 - 0.58%	0.0047
Gastric Cancer	-	-	adenocarcinoma	-	-	0%	0.00 - 0.24%	0.0000
Pancreatic Cancer	6.00	Ferlay J et al. 2018.	adenocarcinoma	80%	Ducreux M et al. 2016.	0.31%	0.09 - 0.53%	0.0149
Liver Cancer	11.00	Ferlay J et al. 2018.	hepatocellular carcinoma	80%	Petrick JL et al. 2016.	0.05%	0.00 - 0.29%	0.0044
Gallbladder/Biliary Tract Cancer	2.90	Ferlay J et al. 2018.	biliary tract carcinoma	100%	NA.	0.20%	0.00 - 0.43%	0.0058

Colorectal Cancer	24.20	Ferlay J et al. 2018.	adenocarcinoma	90%	Hamilton S et al. 2010.	0.26%	0.15 - 0.36%	0.0566
Bladder Cancer	7.20	Ferlay J et al. 2018.	urothelial carcinoma	90%	Bellmunt J et al. 2014.	0.15%	0.00 - 0.97%	0.0097
Adrenal Gland Cancer	-	-	adrenocortical carcinoma	-	-	0%	0.00 - 1.24%	0.0000
Kidney Cancer	0.17	Ferlay J et al. 2018.	congenital mesoblastic nephroma‡	7%	Wang ZP et al. 2014.	21.52 %	13.06 - 32.20%	0.0024
Breast Cancer±	27.60	Ferlay J et al. 2018.	breast carcinoma	100%	NA.	0.14%	0.04 - 0.24%	0.0386
Cervical (cervix uteri) Cancer±	7.55	Ferlay J et al. 2018.	cervical carcinoma	100%	NA.	0.36%	0.00 - 0.81%	0.0272
Uterine Cancer	-	-	uterine/endometrial carcinoma	-	-	0%	0.00 - 0.56%	0.0000
Ovarian Cancer	-	-	ovarian carcinoma	-	-	0%	-	0.0000
Prostate Cancer	-	-	prostate carcinoma	-	-	0%	0.00 - 0.73%	0.0000
Testicular Cancer	-	-	testicular germ cell	-	-	0%	0.00 - 0.64%	0.0000
Melanoma	3.80	Ferlay J et al. 2018.	cutaneous melanoma	100%	NA.	0.31%	0.007 - 0.55%	0.0118
			uveal melanoma	-	-	0%	0.00 - 1.04%	0.0000
Bone Sarcoma	-	-	osteosarcoma	-	-	0%	-	0.0000
	-	-	Ewing sarcoma	-	-	0%	-	0.0000
Soft Tissue Sarcoma	0.01	Ries LAG et al. 1999. (US) NPCR 2016. (US)	infantile fibrosarcoma‡	100%	NA.	90.56 %	67.42 - 100.00 %	0.0059
	0.05	Lovly CM et al. 2014. (US)	inflammatory myofibroblastic tumour	100%	NA.	1.15%	0.00 - 3.70%	0.0006
	0.68	Henley SJ et al. 2018. (US) Benson C et al. 2017. (US)	uterine sarcoma±	100%	NA.	0.34%	0.00 - 0.78%	0.0023
	1.08	Nilsson B et al. 2005.	gastrointestinal stromal tumour	100%	NA.	0.61%	0.00 - 1.65%	0.0066

		(EU) Patel N et al. 2019. (US)						
	-	-	rhabdomyosarcoma	-	-	0%	-	0.0000
Neuroendocrine Tumour	6.61	Chauhan A et al. 2018 (US)	neuroendocrine tumours	100%	NA.	0.26%	0.07 - 0.44%	0.0172
Overall NTRK Gene Fusion Tumour Incidence								0.52

* Head and neck cancer = lip/oral cavity (C00-06), larynx (C32), nasopharynx (C11), oropharynx (C09-10), hypopharynx (C12-13), salivary glands (C07-08).

± Breast cancer, cervical cancer, and uterine sarcoma has been adjusted from per 100,000 females to per 100,000 persons (both genders).

¥ Infantile fibrosarcoma and congenital mesoblastic nephroma have been adjusted from per 100,000 <19 year olds to per 100,000 persons (all ages).

Table S5: Worldwide overall *NTRK* gene fusion tumour 5-year prevalence in 2018

Tumour Type	Tumour 5-Year Prevalence (per 100,000)	Tumour 5-Year Prevalence Reference	Relevant Histology	Histology Proportion Within Tumour	Histology Proportion Reference	NTRK Histology Frequency from SLR MA		NTRK 5-Year Prevalence per Tumour (per 100,000)
						%	95% CI	
Head and Neck Cancer*	30.00	Ferlay J et al. 2018.	squamous cell carcinoma	90%	Gregoire V et al. 2010. Lambert R et al. 2011.	0.38%	0.01 - 0.76%	0.1026
Eye	-	-	retinoblastoma	-	-	0%	-	0.0000
Lacrimal Gland Cancer	0.69	von Holstein SL et al. 2013. (EU)	lacrimal gland carcinoma	100%	NA.	0.29%	0.01 - 1.58%	0.0020
Brain, CNS	10.10	Ferlay J et al. 2018.	glioma	81%	Ostrum QT et al. 2018.	0.99%	0.00 - 2.79%	0.0810
Thyroid Cancer	26.20	Ferlay J et al. 2018.	thyroid carcinoma	100%	-	2.60%	1.83 - 3.37%	0.6812
Thymus	-	-	thymoma	-	-	0%	0.00 - 0.82%	0.0000
Lung Cancer	27.90	Ferlay J et al. 2018.	small cell	13%	Planchard D et al. 2018. Fruh M et al. 2013.	0.32%	0.00 - 1.09%	0.0116
			non-small cell	87%	Planchard D et al. 2018. Fruh M et al. 2013.	0.17%	0.09 - 0.25%	0.0413
Mesothelioma	-	-	mesothelioma	-	-	0%	0.00 - 1.13%	0.0000
Esophageal Cancer	7.20	Ferlay J et al. 2018.	squamous cell carcinoma	90%	Lordick F et al. 2016.	0.07%	0.00 - 0.58%	0.0045
Gastric Cancer	-	-	adenocarcinoma	-	-	0%	0.00 - 0.24%	0.0000
Pancreatic Cancer	3.70	Ferlay J et al. 2018.	adenocarcinoma	80%	Ducreux M et al. 2016.	0.31%	0.09 - 0.53%	0.0092
Liver Cancer	8.80	Ferlay J et al. 2018.	hepatocellular carcinoma	80%	Petrick JL et al. 2016.	0.05%	0.00 - 0.29%	0.0035
Gallbladder/Biliary Tract Cancer	3.10	Ferlay J et al. 2018.	biliary tract carcinoma	100%	NA.	0.20%	0.00 - 0.43%	0.0062

Colorectal Cancer	62.80	Ferlay J et al. 2018.	adenocarcinoma	90%	Hamilton S et al. 2010.	0.26%	0.15 - 0.36%	0.1470
Bladder Cancer	21.60	Ferlay J et al. 2018.	urothelial carcinoma	90%	Bellmunt J et al. 2014.	0.15%	0.00 - 0.97%	0.0292
Adrenal Gland Cancer	-	-	adrenocortical carcinoma	-	-	0%	0.00 - 1.24%	0.0000
Kidney Cancer	0.58	Ferlay J et al. 2018.	congenital mesoblastic nephroma‡	7%	Wang ZP et al. 2014.	21.52 %	13.06 - 32.20%	0.0081
Breast Cancer±	90.90	Ferlay J et al. 2018.	breast carcinoma	100%	NA.	0.14%	0.04 - 0.24%	0.1273
Cervical (cervix uteri) Cancer±	19.50	Ferlay J et al. 2018.	cervical carcinoma	100%	NA.	0.36%	0.00 - 0.81%	0.0702
Uterine Cancer	-	-	uterine/endometrial carcinoma	-	-	0%	0.00 - 0.56%	0.0000
Ovarian Cancer	-	-	ovarian carcinoma	-	-	0%	-	0.0000
Prostate Cancer	-	-	prostate carcinoma	-	-	0%	0.00 - 0.73%	0.0000
Testicular Cancer	-	-	testicular germ cell	-	-	0%	0.00 - 0.64%	0.0000
Melanoma	12.70	Ferlay J et al. 2018.	cutaneous melanoma	100%	NA.	0.31%	0.007 - 0.55%	0.0394
			uveal melanoma	-	-	0%	0.00 - 1.04%	0.0000
Bone Sarcoma	-	-	osteosarcoma	-	-	0%	-	0.0000
	-	-	Ewing sarcoma	-	-	0%	-	0.0000
Soft Tissue Sarcoma	0.04	Ries LAG et al. 1999. (US) NPCR 2016. (US)	infantile fibrosarcoma‡	100%	NA.	90.56 %	67.42 - 100.00 %	0.0327
	0.27	Lovly CM et al. 2014. (US)	inflammatory myofibroblastic tumour	100%	NA.	1.15%	0.00 - 3.70%	0.0031
	1.99	Henley SJ et al. 2018. (US) Benson C et al. 2017. (US)	uterine sarcoma±	100%	NA.	0.34%	0.00 - 0.78%	0.0068
	5.38	Nilsson B et al. 2005. (EU) Patel N et al. 2019. (US)	gastrointestinal stromal tumour	100%	NA.	0.61%	0.00 - 1.65%	0.0328

	-	-	rhabdomyosarcoma	-	-	0%	-	0.0000
Neuroendocrine Tumour	29.87	Chauhan A et al. 2018 (US)	neuroendocrine tumours	100%	NA.	0.26%	0.07 - 0.44%	0.0777
Overall NTRK Gene Fusion Tumour 5-Year Prevalence								1.52

* Head and neck cancer = lip/oral cavity (C00-06), larynx (C32), nasopharynx (C11), oropharynx (C09-10), hypopharynx (C12-13), salivary glands (C07-08).

± Breast cancer, cervical cancer, and uterine sarcoma has been adjusted from per 100,000 females to per 100,000 persons (both genders).

¥ Infantile fibrosarcoma and congenital mesoblastic nephroma have been adjusted from per 100,000 <19 year olds to per 100,000 persons (all ages).